Slideshow

Early Cortical Bone Loss Seen in Non-Radiographic Axial Spondyloarthritis

Be aware that changes in geometry, bone mineral density, and micro-structure appear early in the disease course of axSpA.

Reference1. Neumann A, Haschka J, Kleyer A, et al. Cortical bone loss is an early feature of nonradiographic axial spondyloarthritis. Arthritis Res Ther. 2018;20:202. doi: 10.1186/s13075-018-1620-1.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Related Content
Copper and Iron Associated With Fibromyalgia Risk
February 11th 2025

Copper and Iron Associated With Fibromyalgia Risk

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Richard Furie, MD | Credit: Northwell Health
February 7th 2025

REGENCY: Obinutuzumab Proves Efficacy in Lupus Nephritis

Patrick Campbell
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
FDA Accepts BLA for Golimumab Biosimilar for Inflammatory Conditions
February 6th 2025

FDA Accepts BLA for Golimumab Biosimilar for Inflammatory Conditions

Victoria Johnson
Black and white FDA logo | Credit: US Food and Drug Administration
February 5th 2025

FDA Fast Tracks CAR-T Therapy for Lupus

Abigail Brooks, MA
© 2025 MJH Life Sciences

All rights reserved.